BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30024105)

  • 1. Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.
    Jiang Y; Mei W; Gu Y; Lin X; He L; Zeng H; Wei F; Wan X; Yang H; Major P; Tang D
    Mol Oncol; 2018 Sep; 12(9):1559-1578. PubMed ID: 30024105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy-related circRNA evaluation reveals hsa_circ_0001747 as a potential favorable prognostic factor for biochemical recurrence in patients with prostate cancer.
    Zhong C; Wu K; Wang S; Long Z; Yang T; Zhong W; Tan X; Wang Z; Li C; Lu J; Mao X
    Cell Death Dis; 2021 Jul; 12(8):726. PubMed ID: 34294687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.
    Melbø-Jørgensen C; Ness N; Andersen S; Valkov A; Dønnem T; Al-Saad S; Kiselev Y; Berg T; Nordby Y; Bremnes RM; Busund LT; Richardsen E
    PLoS One; 2014; 9(11):e113039. PubMed ID: 25401698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Lv D; Wu X; Chen X; Yang S; Chen W; Wang M; Liu Y; Gu D; Zeng G
    Cancer Immunol Immunother; 2021 Dec; 70(12):3587-3602. PubMed ID: 33934205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer.
    Krzyzanowska A; Barron S; Higgins DF; Loughman T; O'Neill A; Sheehan KM; Wang CA; Fender B; McGuire L; Fay J; O'Grady A; O'Leary D; Watson RW; Bjartell A; Gallagher WM
    Eur Urol Focus; 2023 Nov; 9(6):983-991. PubMed ID: 37105783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four gene signature predictive of recurrent prostate cancer.
    Komisarof J; McCall M; Newman L; Bshara W; Mohler JL; Morrison C; Land H
    Oncotarget; 2017 Jan; 8(2):3430-3440. PubMed ID: 27966447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Prediction of Prostate Cancer Recurrence through the
    Gu Y; Lin X; Kapoor A; Li T; Major P; Tang D
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of prostate cancer biochemical recurrence by using discretization supports the critical contribution of the extra-cellular matrix genes.
    Marin L; Casado F
    Sci Rep; 2023 Jun; 13(1):10144. PubMed ID: 37349324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms.
    Mei W; Dong Y; Gu Y; Kapoor A; Lin X; Su Y; Vega Neira S; Tang D
    J Adv Res; 2023 Dec; 54():195-210. PubMed ID: 36681115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence.
    Lautert-Dutra W; Melo CM; Chaves LP; Souza FC; Crozier C; Sundby AE; Woroszchuk E; Saggioro FP; Avante FS; Dos Reis RB; Squire JA; Bayani J
    Front Oncol; 2023; 13():1280943. PubMed ID: 37965470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.
    Yang L; Roberts D; Takhar M; Erho N; Bibby BAS; Thiruthaneeswaran N; Bhandari V; Cheng WC; Haider S; McCorry AMB; McArt D; Jain S; Alshalalfa M; Ross A; Schaffer E; Den RB; Jeffrey Karnes R; Klein E; Hoskin PJ; Freedland SJ; Lamb AD; Neal DE; Buffa FM; Bristow RG; Boutros PC; Davicioni E; Choudhury A; West CML
    EBioMedicine; 2018 May; 31():182-189. PubMed ID: 29729848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database.
    Boldrini L; Faviana P; Galli L; Paolieri F; Erba PA; Bardi M
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway.
    Robsahm TE; Tsuruda KM; Hektoen HH; Storås AH; Cook MB; Hurwitz LM; Langseth H
    Acta Oncol; 2023 Jan; 62(1):8-14. PubMed ID: 36762472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference-free transcriptome signatures for prostate cancer prognosis.
    Nguyen HTN; Xue H; Firlej V; Ponty Y; Gallopin M; Gautheret D
    BMC Cancer; 2021 Apr; 21(1):394. PubMed ID: 33845808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk.
    Rasmussen M; Fredsøe J; Salachan PV; Blanke MPL; Larsen SH; Ulhøi BP; Jensen JB; Borre M; Sørensen KD
    NPJ Precis Oncol; 2024 Feb; 8(1):48. PubMed ID: 38395986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prostate cancer tissue metabolomics: would clinics utilise it for diagnosis?
    Bansal N; Kumar M; Sankhwar SN; Gupta A
    Expert Rev Mol Med; 2023 Aug; 25():e26. PubMed ID: 37548191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.
    Gu Y; Chow MJ; Kapoor A; Mei W; Jiang Y; Yan J; De Melo J; Seliman M; Yang H; Cutz JC; Bonert M; Major P; Tang D
    Transl Oncol; 2018 Aug; 11(4):1012-1022. PubMed ID: 29966864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App.
    Dunning MJ; Vowler SL; Lalonde E; Ross-Adams H; Boutros P; Mills IG; Lynch AG; Lamb AD
    EBioMedicine; 2017 Mar; 17():5-6. PubMed ID: 28286059
    [No Abstract]   [Full Text] [Related]  

  • 19. Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.
    An Y; Lu W; Li S; Lu X; Zhang Y; Han D; Su D; Jia J; Yuan J; Zhao B; Tu M; Li X; Wang X; Fang N; Ji S
    Discov Oncol; 2023 Dec; 14(1):234. PubMed ID: 38112859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
    Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
    Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.